Global Triple-negative Breast Cancer Treatment Market Revenue to Cross US$ 720 Mn By 2026- Persistence Market Research

Wednesday, October 3, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 3, 2018 /PRNewswire/ --

Newer Treatment Options

and Emerging Potential of Generic Drugs Key Opportunity Areas in the Triple-Negative Breast Cancer Treatment Market, Says Persistence Market Research

Ongoing advancements in cancer research continue to lead to the introduction of newer and better

treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

     (Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg )

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% - 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Request Sample Report @ https://www.persistencemarketresearch.com/samples/14305

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market 

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Triple Negative Breast Cancer Treatment Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/triple-negative-breast-cancer-treatment-market.asp

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market 

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/methodology/14305

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Get full Report Now https://www.persistencemarketresearch.com/checkout/14305

More from PMR's Life Sciences & Transformational Health Market Intelligence: 

  • Immune Checkpoint Inhibitors Market: segmented on the basis of drug class - PD-1, PD-L1, CTLA-4 ; On the basis of therapeutic application - Lung Cancer, Melanoma Squamous Cell Carcinoma, Urothelial Carcinoma, Blood cancer, Other Cancers ; On the basis of the distribution channel - Hospital Pharmacies, Retail Pharmacieshttps://www.persistencemarketresearch.com/market-research/immune-checkpoint-inhibitors-market.asp
  • Progressive Multifocal Leukoencephalopathy Treatment Market: Segmented Based on drug type anti-retroviral therapy, antiviral/anti JCV and other symptomatic;Based on indication HIV/AIDS, organ transplantation, multiple sclerosis and hematological malignancies;Based on distribution channel hospital pharmacies, drug stores and retail pharmacies https://www.persistencemarketresearch.com/market-research/progressive-multifocal-leukoencephalopathy-treatment-market.asp
  • Rna Based Therapeutics And Vaccines Market: segmented based on product type - RNA-based Therapeutics, RNA-based Vaccines (mRNA); On the basis of indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, genetic diseases & others https://www.persistencemarketresearch.com/market-research/rna-based-therapeutics-and-vaccines-market.asp

Persistence Market Research Overview 

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: sales@persistencemarketresearch.com

PMR Latest News:  https://www.persistencemarketresearch.com/news

SOURCE Persistence Market Research Pvt. Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store